These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 2796604)

  • 1. Analgesic activity of spiradoline mesylate (U-62,066E), a kappa opioid agonist in mice.
    Kunihara M; Ohyama M; Nakano M; Hayashi S
    Life Sci; 1989; 45(13):1191-8. PubMed ID: 2796604
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Analgesic and mechanistic evaluation of spiradoline, a potent kappa opioid.
    Vonvoigtlander PF; Lewis RA
    J Pharmacol Exp Ther; 1988 Jul; 246(1):259-62. PubMed ID: 2839665
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Central monoaminergic mechanisms in mice and analgesic activity of spiradoline mesylate, a selective kappa-opioid receptor agonist.
    Kunihara M; Ohyama M; Nakano M
    Eur J Pharmacol; 1992 Apr; 214(2-3):111-8. PubMed ID: 1325350
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A review of the properties of spiradoline: a potent and selective kappa-opioid receptor agonist.
    Wadenberg ML
    CNS Drug Rev; 2003; 9(2):187-98. PubMed ID: 12847558
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of spiradoline mesylate, a selective kappa-opioid-receptor agonist, on the central dopamine system with relation to mouse locomotor activity and analgesia.
    Kunihara M; Ohyama M; Nakano M
    Jpn J Pharmacol; 1993 Jul; 62(3):223-30. PubMed ID: 8411771
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of a kappa agonist, spiradoline mesylate (U62,066E), on activation and vaginocervical-stimulation produced analgesia in rats.
    Boyle TJ; Masuda T; Cunningham ST
    Brain Res Bull; 2001 Jan; 54(2):213-8. PubMed ID: 11275411
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mu antagonist and kappa agonist properties of beta-funaltrexamine (beta-FNA) in vivo: long-lasting spinal analgesia in mice.
    Qi JA; Heyman JS; Sheldon RJ; Koslo RJ; Porreca F
    J Pharmacol Exp Ther; 1990 Mar; 252(3):1006-11. PubMed ID: 2156986
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Targeting pain-depressed behaviors in preclinical assays of pain and analgesia: drug effects on acetic acid-depressed locomotor activity in ICR mice.
    Stevenson GW; Cormier J; Mercer H; Adams C; Dunbar C; Negus SS; Bilsky EJ
    Life Sci; 2009 Aug; 85(7-8):309-15. PubMed ID: 19559034
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Analgesic activity of anticancer agent suramin.
    Ho BT; Huo YY; Lu JG; Newman RA; Levin VA
    Anticancer Drugs; 1992 Apr; 3(2):91-4. PubMed ID: 1525397
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Lack of tolerance in peripheral opioid analgesia in mice.
    Tokuyama S; Inoue M; Fuchigami T; Ueda H
    Life Sci; 1998; 62(17-18):1677-81. PubMed ID: 9585156
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Intake of a palatable sucrose solution modifies the actions of spiradoline, a kappa opioid receptor agonist, on analgesia and feeding behavior in male and female rats.
    Kanarek RB; Homoleski BA; Wiatr C
    Pharmacol Biochem Behav; 2000 Jan; 65(1):97-104. PubMed ID: 10638642
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Spinal analgesic actions of kappa receptor agonists, U-50488H and spiradoline (U-62066).
    Piercey MF; Einspahr FJ
    J Pharmacol Exp Ther; 1989 Oct; 251(1):267-71. PubMed ID: 2552077
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The influence of the kappa agonist-spiradoline (U62066E) on the analgesic activity of some opioids at the spinal level.
    Stachura Z; Herman ZS
    Pol J Pharmacol; 1994; 46(1-2):37-41. PubMed ID: 7981769
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Analgesic activity of ZC88, a novel N-type voltage-dependent calcium channel blocker, and its modulation of morphine analgesia, tolerance and dependence.
    Meng G; Wu N; Zhang C; Su RB; Lu XQ; Liu Y; Yun LH; Zheng JQ; Li J
    Eur J Pharmacol; 2008 May; 586(1-3):130-8. PubMed ID: 18374913
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A selective kappa-opioid agonist, U-50,488H, blocks the development of tolerance to morphine analgesia in rats.
    Yamamoto T; Ohno M; Ueki S
    Eur J Pharmacol; 1988 Oct; 156(1):173-6. PubMed ID: 2850208
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacological characterization of buprenorphine, a mixed agonist-antagonist with kappa 3 analgesia.
    Pick CG; Peter Y; Schreiber S; Weizman R
    Brain Res; 1997 Jan; 744(1):41-6. PubMed ID: 9030411
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Morphine can produce analgesia via spinal kappa opioid receptors in the absence of mu opioid receptors.
    Yamada H; Shimoyama N; Sora I; Uhl GR; Fukuda Y; Moriya H; Shimoyama M
    Brain Res; 2006 Apr; 1083(1):61-9. PubMed ID: 16530171
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Protein kinase C-mediated acute tolerance to peripheral mu-opioid analgesia in the bradykinin-nociception test in mice.
    Inoue M; Ueda H
    J Pharmacol Exp Ther; 2000 May; 293(2):662-9. PubMed ID: 10773042
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Chronopharmacology of analgesic effect and its tolerance induced by morphine in mice.
    Yoshida M; Ohdo S; Takane H; Tomiyoshi Y; Matsuo A; Yukawa E; Higuchi S
    J Pharmacol Exp Ther; 2003 Jun; 305(3):1200-5. PubMed ID: 12626644
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Streptozotocin-induced diabetes selectively alters the potency of analgesia produced by mu-opioid agonists, but not by delta- and kappa-opioid agonists.
    Kamei J; Ohhashi Y; Aoki T; Kawasima N; Kasuya Y
    Brain Res; 1992 Feb; 571(2):199-203. PubMed ID: 1319265
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.